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Abstract 
Background: Mesenchymal stromal cells are a promising option to treat knee osteoarthritis. Their safety and useful‑
ness must be confirmed and the optimal dose established. We tested increasing doses of bone marrow mesenchymal 
stromal cells (BM‑MSCs) in combination with hyaluronic acid in a randomized clinical trial.
Materials: A phase I/II multicenter randomized clinical trial with active control was conducted. Thirty patients 
diagnosed with knee OA were randomly assigned to intraarticularly administered hyaluronic acid alone (control), or 
together with 10 × 106 or 100 × 106 cultured autologous BM‑MSCs, and followed up for 12 months. Pain and func‑
tion were assessed using VAS and WOMAC and by measuring the knee motion range. X‑ray and magnetic resonance 
imaging analyses were performed to analyze joint damage.
Results: No adverse effects were reported after BM‑MSC administration or during follow‑up. BM‑MSC‑administered 
patients improved according to VAS during all follow‑up evaluations and median value (IQR) for control, low‑dose and 
high‑dose groups change from 5 (3, 7), 7 (5, 8) and 6 (4, 8) to 4 (3, 5), 2 (1, 3) and 2 (0,4) respectively at 12 months (low‑
dose vs control group p = 0.005 and high‑dose vs control group p < 0.009). BM‑MSC‑administered patients were also 
superior according to WOMAC, although improvement in control and low‑dose patients could not be significantly 
sustained beyond 6 months. On the other hand, the BM‑MSC high‑dose group exhibited an improvement of 16.5 (12, 
19) points at 12 months (p < 0.01). Consistent with WOMAC and VAS values, motion ranges remained unaltered in the 
control group but improved at 12 months with BM‑MSCs. X‑ray revealed a reduction of the knee joint space width in 
the control group that was not seen in BM‑MSCs high‑dose group. MRI (WORMS protocol) showed that joint damage 
decreased only in the BM‑MSC high‑dose group, albeit slightly.
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Background
Osteoarthritis (OA) is a chronic disease involving pro-
gressive degeneration of the articular cartilage and sub-
chondral bone, accompanied by synovitis [1]. Due to its 
avascular nature and the limited self-renewal capacity 
of chondrocytes, adult articular cartilage presents lim-
ited repair capability [2]. Current treatment options for 
articular cartilage injury and osteoarthritis are aimed to 
relieve inflammation and pain, but have no effect on the 
natural progression of the disease [3]. To date, in severe 
cases of knee OA, knee replacement is the only therapeu-
tic option [4].
During the last two decades focal cartilage defects 
have been treated using cell therapy and tissue engineer-
ing approaches. In this context, autologous chondro-
cyte implantation (ACI) or matrix-induced autologous 
chondrocyte (MACI) implantation techniques have 
been applied with promising results, although the large 
non-contained cartilage defects found in OA and its 
own pathogenesis cannot be treated using ACI or MACI 
[5–7]. The use of intraarticular injections of mesenchy-
mal stromal cells (MSCs) may represent some advantages 
over chondrocytes in patients with OA. First, because 
of their ability for self-renewal, the number of cells that 
can be obtained is increased without cartilage donor site 
morbidity and with reduced cost [6–8]. Second, MSCs 
are responsible for the normal turnover and mainte-
nance of adult mesenchymal tissues, including cartilage, 
and has been suggested that the number of MSCs pre-
sent in the subchondral bone decreases with age and OA 
grade, suggesting that such MSCs deficit could prime the 
degenerative process [9–12]. It has also been proposed 
that during tissue injury MSCs migrate to participate in 
the reparative process, giving MSCs a potential therapeu-
tic value when added exogenously [13, 14]. Additionally, 
cultured MSCs induce in  vitro chondrocyte prolifera-
tion and extracellular matrix protein synthesis, including 
aggrecan and type II collagen, which support their criti-
cal role in cartilage tissue repair [15, 16].
There is an increasing number of reports on the treat-
ment of OA using MSC, but these are methodologically 
heterogeneous in dose, cell source, coadjuvants and cell 
processing methods, which makes it difficult to com-
pare the different studies [17]. In many cases, treatments 
consist of the administration of bone marrow concen-
trates as a source of MSCs. However, it is well known 
that only 0.001 % of the mononuclear cells found in the 
bone marrow could be considered as MSCs as defined 
by the ICRS in 2006. Therefore, their number in a bone 
marrow concentrate is very limited compared to that 
obtained upon culturing MSCs [18–20]. Only a few stud-
ies using MSCs produced by good manufacture practices 
(GMP) such as advanced cell-therapy products have 
been reported [21–24]. In addition, there is a need to 
explore the effect of different cell doses in a randomized 
way to gain insight into the ideal conditions for knee OA 
patients to take advantage of MSC therapy. For these rea-
sons, the purpose of this study was to randomly assess 
the safety, feasibility and efficacy of the intra-articular 
injection of two different doses of GMP-produced autol-
ogous bone marrow MSCs (BM-MSCs) with hyaluronic 
acid (HA) in patients with knee OA.
Methods
Participants and study design
This is a phase I/II randomized clinical trial with active 
control conducted between August 2012 and Octo-
ber 2014, involving the Clínica Universidad de Navarra 
(Pamplona, Spain) and IBSAL-Hospital Universitario de 
Salamanca (Salamanca, Spain). All the procedures were 
approved by the Institutional Review Board of Nav-
arra and the Spanish Agency of Medicines and Medical 
Devices (Nº EudraCT: 2009-017624-72, Clinical Trials.
gov identifier: NCT02123368). All participants provided 
written informed consent.
Criteria for eligibility of patients
Inclusion criteria were as follows: males and females aged 
50–80, diagnosis of knee OA according to American 
College of Rheumatology criteria, visual analogue scale 
(VAS) joint pain ≥2.5, Kellgren–Lawrence radiological 
classification scale ≥2, body mass index between 20 and 
35  kg/m [2], and availability to be followed during the 
study period; exclusion criteria were: previous diagnosis 
of polyarticular disease, severe mechanical extra-articu-
lar deformation (>15° varus/15° valgus), systemic auto-
immune rheumatic disease, arthroscopy or intraarticular 
infiltration in the last 6 months, chronic treatment with 
Conclusions: The single intraarticular injection of in vitro expanded autologous BM‑MSCs together with HA is a safe 
and feasible procedure that results in a clinical and functional improvement of knee OA, especially when 100 × 106 
cells are administered. These results pave the way for a future phase III clinical trial.
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immunosuppressive or anticoagulant drugs, corticoster-
oids treatment in the 3 last months, nonsteroidal anti-
inflammatory drugs therapy in the last 15 days, bilateral 
knee OA requiring treatment in both knees, poorly con-
trolled diabetes mellitus, blood dyscrasias, and allergy to 
HA or bird proteins.
Treatment groups
Participants were assigned to comparison groups by 
an unblinded computer-generated list, based on unre-
stricted randomization, which was maintained centrally 
by staff with no clinical involvement in the trial so no 
center knew the treatment allocation of any patient until 
the patient had been recruited into the trial.
Three groups were created:
Control group, constituted by patients who received a 
single intra-articular injection of 60  mg HA (Hyalone®) 
in a final volume of 4 ml.
Low-dose BM-MSCs group, constituted by patients 
who received a single intra-articular injection of 10 × 106 
autologous cultured BM-MSC in 1.5  ml Ringer’s lactate 
solution, followed by an intraarticular injection of 4  ml 
HA.
High-dose BM-MSCs group, constituted by patients 
who received a single intra-articular injection of 
100 × 106 autologous cultured BM-MSCs in 3 ml Ring-
er’s lactate solution, followed by an intraarticular injec-
tion of 4 ml HA.
Sample size calculation
We estimated that a sample size of ten patients per group 
was required to detect an effect size of 0.6 with a power 
of 80  %, assuming a balanced allocation to treatment 
groups, and a 5 % type I error probability.
Cell culture
BM-MSCs were generated under good manufacturing 
practice conditions (GMP) with standard operating pro-
cedures. Briefly, bone marrow (100  ml) was harvested 
from the pelvic bone (iliac crest) under sterile condi-
tions. The mononuclear cell fraction was isolated by 
Ficoll density gradient centrifugation (Ficoll-Paque, GE 
Healthcare Bio-Sciences AB, Uppsala, Sweden). Cells, 
ranging between 20  ×  106 and 60  ×  106, were subse-
quently seeded in 175 cm2 flasks with growth medium, 
which consisted of αMEM without ribonucleosides 
(Gibco, Life Technologies, Carlsbad, CA, USA) supple-
mented with 5 % platelet lisate, 2 units/ml heparin, peni-
cillin–streptomycin at 1 % (Gibco) and 1 ng/ml human 
fibroblast growth factor (bFGF) (Sigma-Aldrich, St. 
Louis, MO, USA). The flasks were maintained in culture 
at 37  °C in 5  % CO2 atmosphere. The growth medium 
was changed every 3–4  days. About 10–15  days later, 
colonies were formed and the cells were split with Try-
pLE Select™ (Life Technologies) and seeded at 3000–
5000 cells/cm2. Once 70–80 % confluence was reached, 
cells were split again and cultured until they were 
available at the amounts required to be administered 
to patients. Finally, cells were harvested with TrypLE 
Select™, washed three times with PBS and resuspended 
in Ringer’s lactate buffer (Grifols, Barcelona, Spain) con-
taining 1 % human albumin (Grifols), to be administered 
within 24 h of harvesting of the cells. Cells were charac-
terized according to ISCT criteria. Cells were then ana-
lyzed by flow cytometry (FACSCalibur, BD Biosciences, 
San José, CA, USA) with the appropriate antibodies (BD 
Biosciences) to confirm expression of surface markers 
CD90, CD73 and CD44, as well as absence of CD34 and 
CD45.
Cell injection
Cell injection was performed without radiographic guid-
ance through a lateral patellar approach by three differ-
ent orthopaedic surgeons from both involved centers 
(Additional file  1: Figure S1), 3–4  weeks after the iliac 
crest biopsy had been performed. In 90 % of the patients, 
cells were administered within the first hour after being 
harvested. For this purpose, a 19  G needle was used in 
two consecutive intraarticular injections. In the first one, 
10 × 106 (low dose) or 100 × 106 (high dose) BM-MSCs 
were administered in 1.5 and 3  ml doses respectively. 
Subsequently, 4  ml HA (Hyalone®) were injected using 
the same via.
Outcomes of interest
The occurrence of complications and/or adverse effects 
during the study was registered. In addition, the response 
to the intra-articular infusion of HA with or without BM-
MSCs was assessed using the following procedures:
A goniometer-based evaluation of the articular range of 
motion at baseline i.e. before treatment administration, 
and 3, 6 and 12 months after treatment.
Two scale-based methods Visual Analog Scale (VAS) 
[25] and the Likert version of the Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC) 
[26, 27], evaluated at baseline and 3, 6 and 12  months 
after treatment, to clinically assess pain and function. 
VAS ranges from 0 (maximum relief, i.e., no pain) to 10 
(no relief, i.e., maximal pain). WOMAC comprises three 
subscores: pain, which includes 5 items; stiffness, with 2 
items; and physical function, with 17 items. According to 
previous literature, patients were considered WOMAC 
responders when they reported an improvement of 20 % 
in at least two items together with an improvement of ten 
points in the overall scale [28].
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Rosenberg X-ray projections at baseline and 6 and 
12  months afterwards to provide a radiographic assess-
ment of the joint space width. A custom methacrylate 
patient positioner was used to achieve a comparative 
view (Additional file 2: Figure S2).
A magnetic resonance imaging (MRI) study at baseline 
and 6 and 12  months after treatment. Two experienced 
radiologists evaluated MRI images in a blinded manner 
by assessing the number and location of the lesions, car-
tilage thickness, signal intensity, and subchondral bone 
alteration and volume, following the Whole-Organ Mag-
netic Resonance Imaging Score (WORMS) protocol, in 
which higher score values indicate more damage [29]. 
3T Magnetom TRIO equipment (Siemens, Erlangen, 
Germany) was used following a protocol which included 
an axial T1 weighted image (WI) with slice thickness of 
5  mm, coronal T1 WI (4  mm), sagittal T1 WI (4  mm), 
sagittal T2 FS WI (4 mm) and sagittal gradient echo 3D 
(DESS) (2 mm).
Statistics
The analyses were performed according to treatment 
assignment, and all available data from all patients were 
included in the analyses, following the intention-to-treat 
principle. Descriptive data summaries are presented 
as median [interquartile range (IQR)] or percentages. 
Within each group, the comparison of each clinical 
and radiographic endpoint between the value obtained 
at 6 or 12  months and the baseline value, i.e. the one 
obtained immediately before the administration of the 
treatment, was performed using the Mann–Whitney 
U test. Changes in the same end points over time were 
determined calculating the differences between the 
measurements collected at the 6 or 12-month follow-up 
visit and the baseline visit. Subsequently, comparisons 
between treatment groups were carried out using the 
Kruskal–Wallis test and the Mann–Whitney U test. All 
tests were two-tailed. A p value of 0.05 was considered 
to indicate statistical significance, without adjustment 
for multiple testing. All analyses were performed using 
Stata 14 (StataCorp. 2015. Stata Statistical Software: 
Release 14. College Station, TX: StataCorp LP) and IBM 
SPSS Statistics 20 (IBM Corp. Released 2011. IBM SPSS 




Thirty-two patients were assessed for eligibility, and were 
consecutively randomized to treatment groups (Fig.  1). 
Two patients who had been randomly assigned to the 
control group withdrew consent and were excluded from 
the trial. All the groups showed similar baseline charac-
teristics of age and body mass index. Patients in the three 
groups showed an uneven distribution according to the 
Kellgren–Lawrence scale but without statistical signifi-
cance (p = 0.585, Table 1).
Safety
No serious adverse events or complications derived from 
the procedures or treatments were noted. There were 
no clinically important trends in the results of physical 
examination, vital signs and laboratory tests during the 
study. Articular pain requiring anti-inflammatory treat-
ment during the first 24 h after infiltration was observed 
in 1, 3 and 6 patients in the control, low-dose BM-MSC 
and high-dose BM-MSC groups respectively. All patients 
recovered completely without sequelae and no treatment 
group-dependent differences were detected in the dose 
of required anti-inflammatory drug or in the time that 
passed until recovery.
Clinical assessment of pain and function
VAS and WOMAC clinical scores were used in order to 
obtain the best picture of how patients perceived their 
own evolution. Evaluations were performed before the 
administration of treatment and 3, 6 and 12  months 
afterwards, and the results are summarized in Fig.  2, 
Additional file 3: Table S1 (VAS) and Table 2 (WOMAC). 
The patients that were solely given HA did not show 
changes during follow up in their pain status according 
to VAS (Fig. 2; Additional file 3: Table S1). Furthermore, 
although they initially perceived some improvement 
according to the WOMAC pain and physical function 
subscores, this perception was not significantly sustained 
in the long term (Table 2). Inatraarticular delivery of BM-
MSCs, specially when used at high dose, enabled patients 
to perceive an improvement in their perception of pain in 
their daily activity. On one hand, the VAS score value was 
significantly reduced upon treatment with low and high 
BM-MSC doses at all follow-up times (Fig. 2; Additional 
file 3: Table S1). Furthermore, treatment with 100 × 106 
cells was associated with a significant improvement in all 
WOMAC subscores at 12 months (Table 2). It is impor-
tant to note that, when the overall WOMAC value at 
12 months was subtracted from the baseline value in each 
patient, the median decrease in the score, i.e. the relief of 
the symptoms, was notably larger if patients had been 
treated with BM-MSCs [−6.5 (−19, 4), −14 (−27, 4), and 
−14 (−15, −8), median (IQR), for control, low-dose and 
high-dose BM-MSCs groups respectively]. Thus, only the 
patients who had been treated with BM-MSCs met cri-
teria to be considered WOMAC responders in the long 
term.
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Effect of treatments on the range of knee motion
The knee flexion and extension ranges of motion were 
significantly improved in the patients who were treated 
with BM-MSCs and the effect was seen earlier in patients 
receiving the higher doses of BM-MSC. No improvement 
was seen in patients receiving HA alone (Fig.  3; Addi-
tional file 4: Table S2).
Fig. 1 Study flow diagram. Patients were screened in the two participating centers by using the inclusion and exclusion criteria
Table 1 Baseline characteristics of patients
Unless specified, data are presented as median [interquartile range (IQR)]. OA 
osteoarthritis, K–L Kellgren and Lawrence grading scale of severity of knee OA
Control BM-MSCs
Low-dose High-dose
N 10 10 10
Age (years) 60.3 (55.1, 61.1) 65.9 (59.5, 70.6) 57.8 (55.0, 60.8)
Males, n (%) 7 (70) 4 (40) 8 (80)
BMI (kg/m2) 29.6 (26.2, 30.8) 27.1 (24.4, 31.2) 28.5 (25.8, 31.0)
Time since OA  
diagnosis (years)
6 (2, 8) 9 (4, 12) 10 (7, 15)
K‑L 2, n (%) 4 (40) 1 (10) 3 (30)
K‑L 3, n (%) 2 (20) 2 (20) 3 (30)
K‑L 4, n (%) 4 (40) 7 (70) 4 (40) Fig. 2 VAS scores along the study. The median values of VAS in 
the three groups before administration of treatments and 3, 6 and 
12 months afterwards are presented. *p < 0.05; **p < 0.01 with 
respect to the baseline value of the same group
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Radiological and MRI findings
The analysis of the knee joint space by X-rays during fol-
low up showed a borderline reduction in the control group 
(p = 0.05 at 12 months), which was not observed in patients 
treated with high dose BM-MSC (Table 3; Additional file 5: 
Table S3). The assessment in the low dose group was not 
possible because the baseline value was 0. These results 
suggest that BM-MSC may halt the progressive loss of car-
tilage observed in patients with OA despite the use of HA.
Consistent with the X-Ray results, the analysis of the MRI 
following the WORMS protocol showed a reduction in the 
score value during follow up (Table 4). Patients treated with 
high dose BM-MSCs showed a median improvement of 4 
points at 12 months, with an improvement of 22 points in 
25 % of patients, while there were no signs of improvement 
either in the control or in the low BM-MSC group.
Discussion
The interest in the clinical use of MSCs for the treatment 
of knee OA has recently grown. However, the optimal 
dose and source of cells, as well as the use of coadjuvants, 
are not yet established. In the present clinical trial we used 
two single doses of BM-MSCs, 10 and 100  ×  106 cells, 
coadministered with HA, and compared their effects with 
the single administration of HA in patients with knee OA.
Table 2 WOMAC score before administration of treatments 
and 3, 6 and 12 months afterwards
The values of each one of the three WOMAC subscales as well as the overall 
WOMAC score at baseline and 3, 6 and 12 months afterwards are presented. 
Data are the median (IQR) of each group. Function means physical function. 
*p < 0.05, **p < 0.01 with respect to the baseline value of the same group
WOMAC Time Control BM-MSCs
Low-dose High-dose
Pain Baseline 5.5 (5, 6) 7.5 (5, 9) 4.5 (4, 5)
3 months 3 (1, 3)* 3.5 (3, 7) 3 (2, 5)
6 months 2.5 (1, 5)* 3.5 (3, 7) 3.5 (2, 5)
12 months 2 (1, 6) 3.5 (3, 5) 2.5 (2, 4)*
Stiffness Baseline 2 (1, 3) 4 (2, 5) 2.5 (2, 4)
3 months 2 (1, 2) 2 (0, 4) 2 (1, 2)
6 months 0.5 (0, 2) 1.5 (1, 3)* 2 (1, 3)
12 months 2 (1, 2) 2 (1, 2)* 2 (1, 2)*
Function Baseline 21 (13, 24) 26.5 (23, 32) 19 (12, 25)
3 months 9 (7, 11)* 17.5 (8, 26) 10 (7, 18)
6 months 7.5 (2, 13)* 18 (10, 23) 14.5 (8, 17)
12 months 9.5 (5, 23) 17 (10, 20) 11 (9, 14)*
Overall Baseline 29 (19, 38) 37 (32, 42) 28 (16, 34)
3 months 12 (11, 14)* 25.5 (11, 37) 13 (11, 26)*
6 months 10 (4, 20)* 24 (13, 31) 20 (13, 23)
12 months 13.5 (8, 33) 21.5 (15, 26) 16.5 (12, 19)**
Fig. 3 Knee range of motion along the study. The median values 
expressed in degrees of the goniometric measurements of the 
knee flexion (top) and extension (bottom) ranges of motion before 
administration of treatments and 3, 6 and 12 months afterwards are 
presented. *p < 0.05; **p < 0.01 with respect to the baseline value of 
the high‑dose group. #p < 0.05 with respect to the baseline valued of 
the low‑dose group
Table 3 X-ray measurement of  the evolution of  the knee 
articular interline at 6 and 12 months after the administra-
tion of treatments
For each group of treatment, variation for knee joint space width, which was 
measured in mm, was calculated by subtracting, for each patient of the group, 
the value at 6 or 12 months from the baseline value. Data are presented as the 
median (IQR) of each group
Time Control BM-MSCs
Low-dose High-dose
6 months −3 (−6, 0) 0 (−1, 0) 0 (−1, 1)
12 months −4 (−18, 0) 0 (0, 3) 0 (−1, 2)
Table 4 WORMS score before administration of treatments 
and 6 and 12 months afterwards
The overall WORMS scores at baseline and 6 and 12 months afterwards are 
presented as the median (IQR) of each group. The evolution within each 
treatment group at 12 months is also presented, and was calculated by 
subtracting for each patient the values at 12 months from the corresponding 
baseline values. Data are the median (IQR) of each group
Time Control BM-MSCs
Low-dose High-dose
Baseline 79 (41, 94) 75 (64, 107) 60 (53, 84)
6 months 78 (34, 107) 70 (57, 126) 53 (51, 90)
12 months 83 (25, 95) 90 (67, 140) 53 (46, 82)
12 months evolution −0.5 (−16, 15) 2.5 (−3, 25) −4 (−22, 2)
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We found that the use of BM-MSCs resulted in a signifi-
cant relief of pain symptoms in the long term. According 
to the VAS scores, when BM-MSCs had been adminis-
tered, an improvement was seen from the earliest evalua-
tion and was maintained until the last one, at 12 months, 
at which time point the highest effect was observed. 
Interestingly, this pain reduction was independent of the 
dose of BM-MSCs administered. On the other hand, no 
significant changes in VAS were detected in the control 
group, and the value at 12 months was similar to the one 
registered before the administration of the treatments. 
Accordingly, the analysis of the information provided by 
WOMAC score confirmed that BM-MSCs induced relief 
of pain symptoms. It is interesting to note that, although 
treatment with HA alone was able to reduce the WOMAC 
score during the first 6 months, this improvement was not 
sustained in the long term, but when patients received 
BM-MSCs, a significant reduction in WOMAC score 
was detected at 12 months. In addition, unlike what was 
observed with VAS, only the high dose of BM-MSCs 
showed an efficient reduction in the WOMAC score. 
Furthermore, it is notable that only patients treated with 
high-dose BM-MSCs met the criteria to be considered 
WOMAC responders [28].
The effect of MSCs on pain improvement in knee OA 
is controversial and the literature provides differing 
accounts. One metaanalysis and a comprehensive review 
have been recently published on this topic. Xia et al. [17] 
performed a metaanalysis by managing the results of 
seven clinical trials, concluding that cell treatments were 
not able to reduce pain scores. Unfortunately, the heter-
ogeneity in the methodology used in the different stud-
ies, with different cell production methods and dosage, 
precludes these authors from drawing solid conclusions. 
On the other hand, Rodríguez-Merchán [30] reviewed 
25 articles that reported the use of intra-articular injec-
tion of MSCs in knee OA, finding that MSCs induce pain 
relief and functional improvement in three randomized 
clinical trials which, however, were not comparable to 
ours methodologically. One of them used bone marrow 
concentrate, another used peripheral blood progenitor 
cells, while the third one used cultured autologous BM-
MSCs together with a high tibial osteotomy, which is a 
surgical treatment with a well-known impact on pain 
relief [31–33]. The number of clinical randomized tri-
als comparing different treatment and dosage is limited. 
In an interesting study, Orozco et  al. [24, 34] reported 
an improvement in pain and function with the use of 
a single intra-articular injection of 40  ×  106 cultured 
autologous MSCs in twelve patients. In a more compa-
rable randomized clinical trial, using allogenic MSCs, 
Vega et al. reported good clinical outcomes in pain con-
trol and function when comparing the use of a single 
intra-articular injection of 40  ×  106 cultured allogenic 
MSCs against a single intraarticular injection of HA [23].
Osteoarthritis is not considered a classical inflammatory 
arthropathy due to the absence of neutrophils in the synovial 
fluid and the lack of systemic manifestations of inflammation 
[35]. However, it is frequently associated with inflammation 
signs and symptoms such as joint pain, swelling and stiff-
ness, leading to significant functional impairment and dis-
ability [36]. The improvement in pain scores together with 
the mild effect on function and MRI scores suggests that the 
positive effect of BM-MSCs that we have observed may rely 
on their paracrine function. In support of this notion, MSC 
antiinflammatory properties have been correlated with pain 
reduction elsewhere [37–40]. In addition, the reduction 
in pain scores may explain the positive changes in flexion 
and extension. Although such changes are small, it must be 
noted that a limitation of only a few degrees in flexo-exten-
sion may severely compromise the daily functional activity. 
These improvements together with the findings in the image 
analyses, suggest that MSC-based therapies may be indicated 
in asymptomatic patients with mild OA grade, in whom the 
injected MSCs could be more effective through their parac-
rine function when a healthier cartilage is still present.
The maintenance of the knee joint space width has been 
related to an appropriate cartilage thickness [41]. Unlike 
what happened in the patients that were treated with HA 
only, who experienced a reduction of this space over the 
time of the study, the space width was preserved when 
BM-MSC were also administered, even though the results 
obtained in the patients that had received the low dose 
must be taken cautiously since the baseline value in 25 % 
of them was already zero, which precludes suitable follow-
up. Nevertheless, a difference could be observed between 
the high dose and control groups, which did exhibit com-
parable baseline values. This finding is consistent with 
MRI observations and is in agreement with previous 
reports that also investigated the role of cultured MSCs or 
MSCs embedded in scaffolds in knee OA [23, 24, 42–44].
The required dose of MSCs to treat knee OA efficiently is 
a topic of active research. Recently Jo et al. [12] performed 
a pilot study comparing three doses of cultured adipose 
tissue-derived MSCs (1 × 106, n = 3; 50 × 106, n = 3; and 
100 ×  106, n =  3). They found a significant reduction in 
the VAS score only in the high dose group at 6  months, 
in spite of the small number of patients included. Since 
results were better with the highest dose, they focused on 
this in a second phase of the study 100 × 106 (n = 9), with 
promising results. Our findings also suggest that it is pref-
erable to administer 100 × 106 rather than 10 × 106 cells. 
However, we have to bear in mind that, despite randomi-
zation, the OA degree at recruitment was more severe in 
the patients who received only 10 × 106 cells, which may 
obscure our interpretation of this result.
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It is accepted that OA patients have a MSC deficit that 
leads to a degenerative process, and the number, in vitro 
proliferation and differentiation potential of BM-MSCs 
present in the subchondral bone decreases with age and 
OA grade [10, 11, 45]. However, we were able to obtain a 
sufficient amount of BM-MSCs in osteoarthritis patients, 
regardless of their age or grade of disease [46–49]. We 
have not identified any problems during the process of 
production of autologous BM-MSCs, achieving the num-
ber of autologous BM-MSCs proposed, even though the 
mean age of patients was around 60 years.
The present study is not exempt from limitations. First, 
ethical issues prevented us from performing a double-blinded 
trial. In order to minimize this inconvenience, subjective 
clinical scores were contrasted with objective measures to 
minimize bias. In addition, two independent radiologists 
carried out the MRI analyses in a blinded manner. Second, 
the relatively short duration of the study prevented us from 
analyzing the efficiency of the treatments beyond 1  year 
after the administration of the treatments. Finally, as antici-
pated, the severe initial condition of a portion of patients who 
were going to be administered the low dose of cells may have 
stopped these exerting more beneficial effects.
Conclusions
Our study shows that the single intraarticular injection 
of in vitro expanded autologous BM-MSCs together with 
HA is a safe and feasible procedure that results in a clini-
cal and functional improvement of knee OA, especially 
when 100 × 106 cells are administered. These results pave 
the way for a future phase III clinical trial.
Additional files
Additional file 1: Figure S1. Pattern of treatment administration. BM‑
MSCs (bottom right inset) were administered in two consecutive intraar‑
ticular injections with a 19 G needle using a lateral patellar approach. 
10 × 106 or 100 × 106 cells were injected in 1.5 and 3 ml respectively and 
subsequently 60 mg hyaluronic acid were administered in 4 ml. Patients 
randomized to the control group received solely the second injection.
Additional file 2: Figure S2. A–C, methacrylate patient positioner to 
permit a correct caption of Rosenberg X‑ray projections. The X ray tube 
is placed behind the patient, at the level of the knee and at an angle of 
10° with respect to the horizontal in order to evaluate the knee articular 
width. D, examples of the X‑ray images, obtained at baseline and 6 and 
12 months afterwards, of the knees of three of the recruited patients are 
shown. For each patient, images are comparable to each other, which 
makes it possible to obtain a valid and comparable value of the articular 
line.
Additional file 3: Table S1. VAS before administration of treatments and 
3, 6 and 12 months afterwards.
Additional file 4: Table S2. Goniometric measurements of the knee flex‑
ion and extension ranges of motion before administration of treatments 
and 3, 6 and 12 months afterwards.
Additional file 5: Table S3. X‑ray measurement of the knee articular 
interline before administration of treatments and 6 and 12 months 
afterwards.
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